Veerhealth Care Secures Repeat Order Worth 3.60 Crores from Leading FMCG Company for Skin Care Products
Mumbai, June 2026: Veerhealth Care Limited, a specialist in Ayurvedic medicines and oral care products, has received a repeat order worth 3.60 crores from a leading Fast-Moving Consumer Goods (FMCG) company for Face Care Products. The order is set to be executed within the next 45 days.The buyer is described as an FMCG company operating in both domestic and international markets within the personal and household care segment, and is part of a prominent Business Group with a legacy spanning 125 years.
Veerhealth Care Limited focuses on delivering exceptional and safe daily care experiences through its Ayuveer brand, emphasizing quality and affordability across its range of products. The company specializes in manufacturing Pure Vegetarian toothpaste.
Globally, the company holds a distinct position among small-cap entities due to securing US FDA plant clearance.
Financial Outlook and Growth Targets
Looking ahead, Veerhealth Care has established clear revenue expectations for the coming periods. For the financial year 2026-27, the company is anticipating total revenues ranging between 70 and 75 crores, projecting a PAT of 7 to 10 percent. Management noted that this expectation may be surpassed based on the current order book and ongoing discussions with domestic and international buyers.On a longer term scale, Veerhealth Care Limited aims to achieve a revenue target of 100 crores along with a PAT margin of 10% within the next 24 months.
Stock Price Movement
At the close of trade today, Veerhealth Care Ltd. settled at ₹24.83, gaining 1.51%.The shares traded throughout the day, fluctuating between a low of ₹23.00 and a high of ₹24.85.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.